Reaffirms FY23 revenue view $2.375B-$2.500B, consensus $2.46B. Consensus is for FY23 EPS $1.02. Reaffirms FY23 R&D as % of Revenue view 30%-32 %.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
- BioMarin options imply 2.3% move in share price post-earnings
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Meta Platforms upgraded, Estee Lauder downgraded: Wall Street’s top analyst call
- BioMarin initiated with a Sector Perform at Scotiabank